A Phase I/IIa, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors

Study Identifier:
CA254-0001
CT.gov Identifier:
NCT07160725
EudraCT Identifier:
202552000000
EU Trial (CTIS) Number:
N/A
Study Contact Information:
(210) 593-5651 or [email protected]
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

Aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Breast Cancers
Non-Small Cell Lung Cancer
Head & Neck
Solid Tumor
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
I/II
Sex
Female & Male
Age
18+ years
Study Drug
Drug: Experimental: Part 1Drug: BMS-986517
Read More
Drug: Experimental: Part 2: Cohort ADrug: BMS-986517
Drug: Experimental: Part 2: Cohort BDrug: BMS-986517
Drug: Experimental: Part 2: Cohort CDrug: BMS-986517
Drug: JRCT'Intervention(s)
Drug: Experimental: Part 1
Study Status
Indicates the current recruitment status or the expanded access status
Recruiting

Requirements information
Inclusion criteria
  • * Participants must have an ECOG performance status of 0 to 1.
  • * Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator).
  • * Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic solid tumors, including NSCLC, HNSCC, TNBC, and HR+/HER2- breast cancer.
Exclusion criteria
  • * Participants must not have untreated CNS metastases. Participants are eligible if CNS metastases have been treated and do not require immediate treatment or have been treated and have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment).
  • * Participants must not have concurrent malignancy (present during Screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment.
  • * Participants must not have history of serious recurrent infections.
  • * Participants must not have impaired cardiac function or history of severe heart disease.
  • * Other protocol-defined inclusion/exclusion criteria apply.

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Madrid, Spain (FJD)
Madrid, Spain, 28040
Investigator
Status
Will Be Recruiting
Condition(s) Treated at Site
Breast Cancers
Non-Small Cell Lung Cancer
Head & Neck
Solid Tumor